ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / AMLX / financials
XENE (37) OGN (70) IRON (54) ACAD (49) ⌘ Pro Terminal →

Amylyx Pharmaceuticals Inc. (AMLX) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$28.04 -2.84% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $27.84

Amylyx Pharmaceuticals Inc. (AMLX) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $3.62B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on AMLX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is AMLX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $28.04 (-2.84% 1D, market cap $3.62B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, AMLX ranks #480 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does AMLX compare to XENE and OGN in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AMLX carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, XENE (Xenon Pharmaceuticals Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $3.62B) and OGN (Organon & Co.) posts a B- grade (70/100 RQD, P/E 19.4x, ROIC 24.9%, cap $3.63B). Among the 5-stock peer group, ACAD leads on earnings multiple (9.1x) while OGN leads on capital efficiency (24.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for AMLX?
▼

Per AMLX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001658551), Amylyx Pharmaceuticals Inc. generated $429.2M in revenue (+391.3% YoY), -$144.7M in net income, and -$123.5M in free cash flow against $332.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $27.84 (-0.70%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510039
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (6)Whales (10)SEC (10)Macro (10)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-8.6% Base Target
$43 Bull$26 Base$20 Bear
📬 FREE AMLX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AMLX)Realized 20D OHLCV Swing Band: ±9.6%
Deterministic 5-Pillar Attribution (39/100 Composite)
🔍 WHY AMLX SCORES 39/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+10/20 pts (26% of score)

20D Institutional Volume Accumulation (±9.6% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
31
Grade E$26.85+7.2% Next Q
Q2 (-2Q)
34
Grade E$28.77-1.6% Next Q
Q3 (-1Q)
36
Grade E$28.30-0.9% Next Q
Current
39
Grade D-$28.04-7.6% Hist 90D α
Trajectory: E (31) → D- (39)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a AMLX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While AMLX currently carries a cautious 39/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($30.51) and Max Pain ($29.44) forces dealer call-delta covering toward $43.20.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AMLX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “AMLX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 39%NO 61%Trade / Inspect Odds →
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How AMLX Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)
Revenue$429.2MGross Profit $223.2M (52%)Cost of Sales $206.0MOp Profit $0 (0%)OpEx (R&D/SG&A) $223.2MNet Profit$0 (0%)Tax/Other $0

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow
FY23
Rev $380.8M
FY24
Rev $87.4M
FY25
Rev $429.2M
Fiscal YearRevenueGross MarginOp MarginNet ProfitFree Cash FlowROIC %
FY 2025$429.2M52%-35.7%-$144.7M-$123.5M-45%
FY 2024$87.4M93.2%-80%-$301.7M-$167.8M-45%
FY 2023$380.8M52%10.2%$49.3M$11.9M-35%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AMLX)

  • ✓Walkthrough of AMLX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
AMLX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +70.35%🛡️ HOLDING TREND SUPPORT
2026-11-03O $28.68H $28.86L $28.04C $28.04VOL 989.5K
RES: $36.91SUP: $27.50SMA50: $30.51SMA200: $20.23
$43.15$34.83$26.50$18.18$9.86RES $36.91SUP $27.50$28.042026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AMLX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AMLX Butterfly Map → + Track AMLX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +391.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on AMLX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AMLX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AMLX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AMLX)

Health Care Rank #480 of 1015 ⚔️ XENE vs AMLX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AMLX vs. XENE, OGN, IRON, ACAD)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Amylyx Pharmaceuticals Inc. (AMLX) ranks #480 by composite RQD confidence (39/100, grade D-) and #190 by equity capitalization ($3.62B). Within this direct 5-issuer industry benchmark cohort, ACAD leads on earnings valuation at 9.1x trailing P/E, while OGN leads on capital efficiency and profitability with 24.9% ROIC and 53.3% gross margin. OGN currently holds the highest overall quantitative score in the immediate peer group at 70/100 (B-) compared with AMLX at 39/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
AMLX ACTIVE
Amylyx Pharmaceuticals Inc.
D- 39/100 — — -35.0% -2.84% $3.62B Benchmark Subject
XENE
Xenon Pharmaceuticals Inc.
D- 37/100 — — -35.0% +0.56% $3.62B /xene-vs-amlx →
OGN
Organon & Co.
B- 70/100 19.4x 53.3% 24.9% -0.14% $3.63B /ogn-vs-amlx →
IRON
Disc Medicine Inc.
D+ 54/100 — — -27.5% -2.75% $3.59B /iron-vs-amlx →
ACAD
ACADIA Pharmaceuticals Inc.
D 49/100 9.1x 91.7% 7.9% -0.58% $3.55B /acad-vs-amlx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001658551 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Amylyx Pharmaceuticals Inc. (AMLX) reported GAAP revenue of $429.2M (+391.3% vs. FY2024 revenue of $87.4M , and +12.7% cumulative change since FY2023) , GAAP net income of -$144.7M, operating cash flow of -$123.3M, and free cash flow of -$123.5M (+26.4% YoY). On the balance sheet, AMLX closed FY2025 with $332.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $429.2M -$144.7M -$123.3M -$123.5M $332.6M —
FY2024 (FY) 2024-12-31 $87.4M -$301.7M -$167.6M -$167.8M $193.6M —
FY2023 (FY) 2023-12-31 $380.8M $49.3M $11.9M $11.9M — —

3. AMLX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AMLX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $28.04 (-2.84% 1D, market cap $3.62B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, AMLX ranks #480 in composite RQD confidence.

How does AMLX compare to XENE and OGN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AMLX carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, XENE (Xenon Pharmaceuticals Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $3.62B) and OGN (Organon & Co.) posts a B- grade (70/100 RQD, P/E 19.4x, ROIC 24.9%, cap $3.63B). Among the 5-stock peer group, ACAD leads on earnings multiple (9.1x) while OGN leads on capital efficiency (24.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for AMLX?

Per AMLX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001658551), Amylyx Pharmaceuticals Inc. generated $429.2M in revenue (+391.3% YoY), -$144.7M in net income, and -$123.5M in free cash flow against $332.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is AMLX trading relative to its 50-day, 200-day, and 52-week technical levels?

AMLX last traded at $28.04 (-2.84% on volume of 1,161,875 shares), positioning the stock -8.10% below its 50-day simple moving average ($30.51) and +38.61% above its 200-day simple moving average ($20.23). Across its 52-week range of $10.83 to $41.14, AMLX sits at the 56.8% percentile with a 14-day RSI of 51.9 (NEUTRAL RANGE) and an implied next-earnings move of ±9.6% ($25.35 to $30.73).

Direct Sub-Reports: AMLX RQD Cockpit AMLX 12M Forecast AMLX Earnings & Move AMLX Dividends & DRIP AMLX Insiders & 13F AMLX Whale Options AMLX Profit Sankey AMLX News & Why
ROARABLE RATING BRIEF • RQD 39/100 (D-) ✓ SEC XBRL & RQD VERIFIED

AMLX — Amylyx Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Amylyx Pharmaceuticals Inc. (AMLX) earns a live Roarable RQD composite score of 39/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $28.04 (-2.84% 1D, market capitalization $3.62B).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -3.43%.
  • Whale 13F & Options Flow (10/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Amylyx Pharmaceuticals Inc. (AMLX) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. The company carries a market capitalization of $3.6B per the market data. Reported revenue was $380.8M for FY 2023, $87.4M for FY 2024, and — for FY 2025. — describes the company's specific products, customers, or revenue model.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Amylyx Pharmaceuticals Inc. (AMLX) reported $429.2M in annual revenue (up from $87.4M in FY2024, +391.3% YoY) and -$144.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($380.8M revenue, $49.3M net income) through FY2025, AMLX scaled operating cash flow to -$123.3M and free cash flow to -$123.5M, backed by $332.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 39/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -3.43% and institutional whale pillar of 10/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $10.83 – $41.14 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Sector and industry classifications are Health Care and Biotechnology: Pharmaceutical Preparations, but no sector correlation data is provided. No 2nd-order bottlenecks are identified in the source data.

  • Key Question #1: Can AMLX sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $429.2M and free cash flow of -$123.5M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is AMLX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

AMLX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Amylyx Pharmaceuticals Inc. (AMLX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to AMLX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

AMLX Bull vs. Bear Conversation Board — What's Your Call at $28.04?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AMLX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on AMLX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $35.50 (+23.0%)
📌 Pinned Debate

A reported 12-month price target raised to $43 implies 59% upside from the current price, and reported cash increased to $226.7M in FY

The street is overcomplicating Amylyx Pharmaceuticals Inc. (AMLX). A reported 12-month price target raised to $43 implies 59% upside from the current price, and reported cash increased to $226.7M in FY 2025.. With an RQD score of 39/100 (D-) and Forensic Balance Sheet at 10/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $31.17.

SectorRotator 🐂 BULL

@MultipleCompression Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $23.38 (-19.0%)
Spot @ $28.86

Reported net income fell to -$144.7M in FY 2025 with ROIC at -35% and FCF yield at -3.43%, while revenue dropped to $0.0M.

I respect the product at Amylyx Pharmaceuticals Inc., but the stock at $28.86 is a different story. Reported net income fell to -$144.7M in FY 2025 with ROIC at -35% and FCF yield at -3.43%, while revenue dropped to $0.0M.. FCF yield is -3.43% and RQD sits at 39/100 (D-) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%